abstract：BACKGROUND:Cenobamate is a novel tetrazole-derived carbamate compound with a dual mechanism of action. This drug can enhance the inactivated state of voltage-gated sodium channels, preferentially inhibiting the persistent component of the sodium channel current, and acts as a positive allosteric modulator of GABAA rece...

journal_title：CNS drugs

authors： Lattanzi S,Trinka E,Zaccara G,Striano P,Del Giovane C,Silvestrini M,Brigo F

更新日期：2020-11-01 00:00:00

abstract：:Existing drug delivery methods have not led to a significant increase in survival for patients with malignant primary brain tumors. While the combination of conventional therapies consisting of surgery, radiotherapy, and chemotherapy has improved survival for some types of brain tumors (e.g., WNT medulloblastoma), oth...

journal_title：CNS drugs

authors： Haumann R,Videira JC,Kaspers GJL,van Vuurden DG,Hulleman E

更新日期：2020-11-01 00:00:00

abstract：:Glutamatergic, noradrenergic, serotonergic, and cholinergic systems play a critical role in the basal ganglia circuitry. Targeting these non-dopaminergic receptors remains a focus of ongoing research to improve Parkinson's disease (PD) motor symptoms, without the potential side effects of dopamine replacement therapy....

journal_title：CNS drugs

authors： Gonzalez-Latapi P,Bhowmick SS,Saranza G,Fox SH

更新日期：2020-10-01 00:00:00

abstract：INTRODUCTION:Both levetiracetam (LEV) and brivaracetam (BRV) eliminate the electroencephalogram photoparoxysmal response (PPR) in the human phase IIa photosensitivity model of epilepsy. The physiochemical properties of BRV differ from those of LEV, having higher potency and lipophilicity plus 10- to 15-fold greater aff...

journal_title：CNS drugs

authors： Reed RC,Rosenfeld WE,Lippmann SM,Eijkemans RMJC,Kasteleijn-Nolst Trenité DGA

更新日期：2020-10-01 00:00:00

abstract：:The coronavirus 2019 (COVID-19) pandemic is expected to linger. Decisions regarding initiation or continuation of disease-modifying therapy for multiple sclerosis have to consider the potential relevance to the pandemic. Understanding the mechanism of action and the possible idiosyncratic effects of each therapeutic a...

journal_title：CNS drugs

authors： Zheng C,Kar I,Chen CK,Sau C,Woodson S,Serra A,Abboud H

更新日期：2020-09-01 00:00:00

abstract：:The pervasive and devastating nature of substance use disorders underlies the need for the continued development of novel pharmacotherapies. We now know that glia play a much greater role in neuronal processes than once believed.  The various types of glial cells (e.g., astrocytes, microglial, oligodendrocytes) partic...

journal_title：CNS drugs

authors： Jones JD

更新日期：2020-07-01 00:00:00

abstract：:Alzheimer's disease (AD) is the most prevalent dementia in the world. Its cause(s) are presently largely unknown. The most common explanation for AD, now, is the amyloid cascade hypothesis, which states that the cause of AD is senile plaque formation by the amyloid β peptide, and the formation of neurofibrillary tangl...

journal_title：CNS drugs

authors： Fülöp T,Munawara U,Larbi A,Desroches M,Rodrigues S,Catanzaro M,Guidolin A,Khalil A,Bernier F,Barron AE,Hirokawa K,Beauregard PB,Dumoulin D,Bellenger JP,Witkowski JM,Frost E

更新日期：2020-07-01 00:00:00

abstract：INTRODUCTION:Cognitive impairment is prevalent and debilitating among persons with multiple sclerosis (MS). While many pharmacologic treatments have shown good efficacy in reducing clinical relapses, brain lesions, and improving certain physical symptoms, their efficacy for improving cognitive function is not well unde...

journal_title：CNS drugs

authors： Chen MH,Goverover Y,Genova HM,DeLuca J

更新日期：2020-06-01 00:00:00

abstract：:There is escalating interest in cell-based therapies to restore lost dopamine inputs in Parkinson's disease. This is based upon the rationale that implanting dopamine progenitors into the striatum can potentially improve dopamine-responsive motor symptoms. A rich body of data describing clinical trials of previous cel...

journal_title：CNS drugs

authors： Henchcliffe C,Sarva H

更新日期：2020-06-01 00:00:00

abstract：:Multiple stimulant and non-stimulant medications are approved for the treatment of attention-deficit/hyperactivity disorder (ADHD), one of the most prevalent childhood neurodevelopmental disorders. Choosing among the available agents and determining the most effective ADHD medication for a given child can be a time-co...

journal_title：CNS drugs

authors： Elsayed NA,Yamamoto KM,Froehlich TE

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:Dravet syndrome (DS) is one of the most severe forms of drug-resistant epilepsy and available interventions fail to control seizures in most patients. Cannabidiol (CBD) is the first in a new class of antiepileptic drugs with a distinctive chemical structure and mechanism of action. OBJECTIVE:The aim of this...

journal_title：CNS drugs

authors： Lattanzi S,Brigo F,Trinka E,Zaccara G,Striano P,Del Giovane C,Silvestrini M

更新日期：2020-03-01 00:00:00

abstract：:Despite the established efficacy of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies, translating CAR T therapy to solid tumors has remained investigational. Glioblastoma, the most aggressive and lethal form of primary brain tumor, has recently been among the malignancies being trialed clinic...

journal_title：CNS drugs

authors： Salinas RD,Durgin JS,O'Rourke DM

更新日期：2020-02-01 00:00:00

abstract：BACKGROUND:Diroximel fumarate (DRF) is a novel oral fumarate approved in the USA for relapsing forms of multiple sclerosis. DRF is converted to monomethyl fumarate, the pharmacologically active metabolite of dimethyl fumarate (DMF). DRF 462 mg and DMF 240 mg produce bioequivalent exposure of monomethyl fumarate and are...

journal_title：CNS drugs

authors： Naismith RT,Wundes A,Ziemssen T,Jasinska E,Freedman MS,Lembo AJ,Selmaj K,Bidollari I,Chen H,Hanna J,Leigh-Pemberton R,Lopez-Bresnahan M,Lyons J,Miller C,Rezendes D,Wolinsky JS,EVOLVE-MS-2 Study Group.

更新日期：2020-02-01 00:00:00

abstract：:Mutations in the isocitrate dehydrogenase (IDH) 1 gene are commonly found in human glioma, with the majority of low-grade gliomas harboring a recurrent point mutation (IDH1 R132H). Mutant IDH reveals an altered enzymatic activity leading to the synthesis of 2-hydroxyglutarate, which has been implicated in epigenetic m...

journal_title：CNS drugs

authors： Karpel-Massler G,Nguyen TTT,Shang E,Siegelin MD

更新日期：2019-12-01 00:00:00

abstract：:Satisfactory management of Parkinson's disease is a challenge that requires a tailored approach for each individual. In the advanced phase of the disease, patients may experience motor complications despite optimized pharmacological therapy. Apomorphine, a short-acting D1- and D2-like receptor agonist, is the only dru...

journal_title：CNS drugs

authors： Carbone F,Djamshidian A,Seppi K,Poewe W

更新日期：2019-09-01 00:00:00

abstract：:Methylene blue is a long-established drug with complex pharmacology and multiple clinical indications. Its diverse mechanisms of action are most likely responsible for the large variety of its clinical effects. Of interest to psychiatrists, methylene blue has antidepressant, anxiolytic, and neuroprotective properties ...

journal_title：CNS drugs

authors： Alda M

更新日期：2019-08-01 00:00:00

abstract：BACKGROUND:Statin use has been frequently associated with depressive symptoms in an older population. However, the nature of this association is uncertain in the literature. In this study, we aimed to investigate the association of statin intake and the prevalence of depressive symptoms in healthy community-dwelling ol...

journal_title：CNS drugs

authors： Agustini B,Mohebbi M,Woods RL,McNeil JJ,Nelson MR,Shah RC,Murray AM,Ernst ME,Reid CM,Tonkin A,Lockery JE,Berk M,ASPREE Investigator Group.

更新日期：2019-07-01 00:00:00

abstract：:Tramadol-an atypical opioid analgesic-has a unique pharmacokinetic and pharmacodynamic profile, with opioidergic, noradrenergic, and serotonergic actions. Tramadol has long been used as a well-tolerated alternative to other drugs in moderate pain because of its opioidergic and monoaminergic activities. However, cumula...

journal_title：CNS drugs

authors： Barakat A

更新日期：2019-05-01 00:00:00

abstract：:The neuronal ceroid lipofuscinoses comprise a group of neurodegenerative lysosomal storage disorders caused by mutations in at least 13 different genes and primarily affect the brain and the retina of children or young adults. The disorders are characterized by progressive neurological deterioration with dementia, epi...

journal_title：CNS drugs

authors： Kohlschütter A,Schulz A,Bartsch U,Storch S

更新日期：2019-04-01 00:00:00

abstract：:Schizophrenia is a long-term psychiatric disorder that impacts important mental functions and requires indefinite treatment, as well as psychosocial and economic support. The introduction of chlorpromazine, the first antipsychotic, and the subsequent development of a long list of similar dopamine-blocking antipsychoti...

journal_title：CNS drugs

authors： Awad AG

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:Walking impairment is a hallmark of multiple sclerosis (MS). It affects > 90% of individuals over time, reducing independence and negatively impacting health-related quality of life, productivity, and daily activities. Walking impairment is consistently reported as one of the most distressing impairments by ...

journal_title：CNS drugs

authors： Hobart J,Ziemssen T,Feys P,Linnebank M,Goodman AD,Farrell R,Hupperts R,Blight AR,Englishby V,McNeill M,Chang I,Lima G,Elkins J,ENHANCE study investigators.

更新日期：2019-01-01 00:00:00

abstract：:NEDA was evaluated as the proportion of patients free of relapses, 3-month confirmed disability progression, and free of new or newly enlarging T2 lesion and Gadolinium enhancing lesions. ...

journal_title：CNS drugs

authors： Papadopoulos D,Mitsikostas DD

更新日期：2019-01-01 00:00:00

abstract：:The basal ganglia and dopaminergic pathways play a central role in hyperkinetic movement disorders. Vesicular monoamine transporter 2 (VMAT2) inhibitors, which deplete dopamine at presynaptic striatal nerve terminals, are a class of drugs that have long been used to treat hyperkinetic movement disorders, but have rece...

journal_title：CNS drugs

authors： Tarakad A,Jimenez-Shahed J

更新日期：2018-12-01 00:00:00

abstract：:The original article can be found online. ...

journal_title：CNS drugs

authors： Chidambaran V,Costandi A,D'Mello A

更新日期：2018-09-01 00:00:00

abstract：:The development of an intervention to slow or halt disease progression remains the greatest unmet therapeutic need in Parkinson's disease. Given the number of failures of various novel interventions in disease-modifying clinical trials in combination with the ever-increasing costs and lengthy processes for drug develo...

journal_title：CNS drugs

authors： Athauda D,Foltynie T

更新日期：2018-08-01 00:00:00

abstract：:Spinal muscular atrophy (SMA) is a rare autosomal recessive neuromuscular disorder most commonly caused by a deletion or mutation in the survival motor neuron 1 (SMN1) gene, which leads to insufficient levels of survival motor neuron (SMN) protein. In such patients, SMN protein production relies on the SMN2 gene. Nusi...

journal_title：CNS drugs

authors： Hoy SM

更新日期：2018-07-01 00:00:00

abstract：BACKGROUND:Although levodopa is considered the most effective pharmacotherapy for motor symptoms of Parkinson's disease (PD), chronic use is associated with motor complications, including fluctuating response and unpredictable, involuntary movements called dyskinesia. ADS-5102 (amantadine) extended-release (ER) capsule...

journal_title：CNS drugs

authors： Elmer LW,Juncos JL,Singer C,Truong DD,Criswell SR,Parashos S,Felt L,Johnson R,Patni R

更新日期：2018-04-01 00:00:00

abstract：:Dravet syndrome (DS) is a medically refractory epilepsy that onsets in the first year of life with prolonged seizures, often triggered by fever. Over time, patients develop other seizure types (myoclonic, atypical absences, drops), intellectual disability, crouch gait and other co-morbidities (sleep problems, autonomi...

journal_title：CNS drugs

authors： Knupp KG,Wirrell EC

更新日期：2018-04-01 00:00:00

abstract：BACKGROUND:Statins possess neuroprotective effects. However, real-world evidence supporting their utility in post-stroke epilepsy (PSE) prevention is limited. OBJECTIVE:The association between statin use, including timing of prescribing (pre-stroke vs post-stroke), type (lipophilicity, intensity of therapy) and dose i...

journal_title：CNS drugs

authors： Lin FJ,Lin HW,Ho YF

更新日期：2018-04-01 00:00:00

abstract：:The issue of antipsychotic treatment during pregnancy is subject to substantial uncertainty and some controversy among healthcare providers, specifically pertaining to second-generation antipsychotics (SGAs) that are subject to a large gap in safety data during pregnancy compared with antidepressants. The amount of sa...

journal_title：CNS drugs

authors： Damkier P,Videbech P

更新日期：2018-04-01 00:00:00

abstract：:All antipsychotics, including the atypical antipsychotics (AAPs), may cause tardive dyskinesia (TD), a potentially irreversible movement disorder, the pathophysiology of which is currently unknown. The prevention and treatment of TD remain major challenges for clinicians. We conducted a PubMed search to review the pre...

journal_title：CNS drugs

authors： Stegmayer K,Walther S,van Harten P

更新日期：2018-02-01 00:00:00

abstract：:Ursolic acid is a pentacyclic triterpenoid found in several plants. Despite its initial use as a pharmacologically inactive emulsifier in pharmaceutical, cosmetic and food industries, several biological activities have been reported for this compound so far, including anti-tumoural, anti-diabetic, cardioprotective and...

journal_title：CNS drugs

authors： Ramos-Hryb AB,Pazini FL,Kaster MP,Rodrigues ALS

更新日期：2017-12-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Patients with focal seizures recruited into adjunctive antiepileptic drug (AED) trials have become more refractory and severe over time; concurrently, placebo responses have increased. To attempt to account for heterogeneity among trials, propensity-score weighted patient-level data were used t...

journal_title：CNS drugs

authors： Swallow E,Fang A,Signorovitch J,Plumb J,Borghs S

更新日期：2017-10-01 00:00:00

abstract：:Sodium channel blockers have been the mainstay of the pharmacological management of focal and generalised tonic-clonic seizures for more than 70 years. The focus of this paper will be on phenytoin, carbamazepine, lamotrigine, oxcarbazepine, rufinamide, lacosamide and eslicarbazepine acetate. All these antiepileptic dr...

journal_title：CNS drugs

authors： Brodie MJ

更新日期：2017-07-01 00:00:00

abstract：:Multiple sclerosis (MS) has a profound impact on health-related quality of life (HRQoL), a comprehensive subjective measure of the patient's health status. Assessment of HRQoL informs on the potential advantages and disadvantages of disease-modifying drugs (DMDs) beyond their effects on observer-based disability and m...

journal_title：CNS drugs

authors： Jongen PJ

更新日期：2017-07-01 00:00:00

abstract：:Infections are common in people with dementia, and antibiotic use is widespread, albeit highly variable, across healthcare settings and countries. The few studies conducted to date that consider the appropriateness of antibiotic prescribing specifically for people with dementia focus on people with advanced dementia a...

journal_title：CNS drugs

authors： Parsons C,van der Steen JT

更新日期：2017-06-01 00:00:00

abstract：:Premature mortality due to cardiovascular disease in those with schizophrenia is the largest lifespan disparity in the US and is growing; adults in the US with schizophrenia die, on average, 28 years earlier than those in the general population. The rate of smoking prevalence among individuals with schizophrenia is es...

journal_title：CNS drugs

authors： Cather C,Pachas GN,Cieslak KM,Evins AE

更新日期：2017-06-01 00:00:00

abstract：BACKGROUND:A recent large database analysis raised concerns of potential acute kidney injury (AKI) risk associated with antipsychotics. However, whether individual atypical and typical antipsychotics are associated with differential AKI risks has not been investigated. OBJECTIVE:The current study compared the risks of...

journal_title：CNS drugs

authors： Jiang Y,McCombs JS,Park SH

更新日期：2017-04-01 00:00:00

abstract：:Parkinson's disease is a disabling hypokinetic neurological movement disorder in which the aetiology is unknown in the majority of cases. Current pharmacological treatments, though effective at restoring movement, are only symptomatic and do nothing to slow disease progression. Electrophysiological, epidemiological an...

journal_title：CNS drugs

authors： Swart T,Hurley MJ

更新日期：2016-12-01 00:00:00

abstract：BACKGROUND:Earlier commencement of clozapine has been related to a better response in treatment-resistant schizophrenia. OBJECTIVES:To identify variables that predict clozapine use after a first episode of schizophrenia (FES). METHODS:Patients with FES and ≤15 days of lifetime antipsychotic treatment were followed up...

journal_title：CNS drugs

authors： Üçok A,Çıkrıkçılı U,Ergül C,Tabak Ö,Salaj A,Karabulut S,Correll CU

更新日期：2016-10-01 00:00:00